Meenu Karson

BioXell SpA provides medical services. The company researches and develops drugs to treat urological, inflammatory, and related disorders. The company was founded in 2002 and is headquartered in Segrate, Italy.

Allozyne, Inc. operates as a biotechnology company that develops and manufactures pharmaceutical products. The firm focuses on manufacture of protein therapeutics for the medical need in autoimmune diseases and cancer. The company was founded by David A. Tirrell, Deepshikha Datta, and William A. Goddard, III in March 2004 and is headquartered in Seattle, WA.

Proteostasis Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It engages in the discovery and development of novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company was founded by William Balch, Jeffery W. Kelly, Andrew Dillin, Richard I. Morimoto, Alfred Lewis Goldberg, Daniel Finley, Christopher T. Walsh, and Randall W. King in 2006 and is headquartered in Boston, MA.

Fore Biotherapeutics, Inc. develops tumor specific driver mutations. It offers fully automated live-cell screening from NGS data. The company was founded by Haim Gil-Ad and Yoram Altschuler in 2011 and is headquartered in Philadelphia, PA.

Vallon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on the development and commercialization of proprietary biopharmaceutical products. The firm's primary product is Abuse-Deterrent Amphetamine Immediate and its product pipeline includes ADAIR, ADMIR, ADHD, and Narcolepsy. The company was founded by David C. Baker on January 11, 2018 and is headquartered in Philadelphia, PA.

Onsero Therapeutics Inc is a preclinical neurobiology company that focuses on discovering and developing small molecule drugs to treat a range of neuropsychiatric and mental health conditions by targeting G-protein-coupled receptors (GPCRs). The company is based in Boston, MA. The company's mission is to provide safe and convenient pharmaceutical options to patients. Meenu Karson has been the CEO of the company since 2021.

Vasomune Therapeutics, Inc. operates as an early stage biopharmaceutical company. It develops medicines to harness the body’s ability to defend against illness by modifying cellular response to disease. The company is headquartered in Toronto, Canada.